Ribavirin with or without alpha interferon for chronic hepatitis C.

Area of Science:

• Hepatology
• Virology
• Clinical Trials

Background:

• Chronic hepatitis C is a significant cause of liver disease, morbidity, and mortality.
• Interferon-based therapies are standard, but efficacy in relapsers and non-responders requires further evaluation.
• Ribavirin's role, alone or with interferon, in previously treated patients is not well-established.

Purpose of the Study:

• To evaluate the efficacy and safety of ribavirin, with or without alpha interferon, for chronic hepatitis C.
• To assess treatment outcomes in interferon-naive patients, relapsers, and non-responders.
• To compare combination therapy against interferon monotherapy or placebo.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials.
• Searches conducted across major electronic databases (MEDLINE, EMBASE, Cochrane Library) and manual searches.
• Primary outcomes: sustained virological response, morbidity, and mortality. Secondary outcomes: biochemical response, histology, quality of life, and adverse events.

Main Results:

• Ribavirin monotherapy showed no significant effect on virological response or histology.
• Combination therapy significantly improved sustained virological response in naive patients (26%), relapsers (33%), and non-responders (11%) compared to interferon alone.
• Combination therapy also improved sustained biochemical response and histology but increased adverse events and treatment discontinuation.

Conclusions:

• Combination therapy with ribavirin and interferon enhances sustained virological, biochemical, and histological responses in chronic hepatitis C patients across different treatment groups.
• The benefits of combination therapy are accompanied by an increased incidence of adverse events.
• Further research may be needed to optimize treatment strategies balancing efficacy and safety.